Abstract
Bosutinib (SKI-606) is a 7-alkoxy-3-quinolinecarbonitrile, which functions as a dual inhibitor of Src and Abl kinases. In biochemical and proliferation assays, the compound was shown to be active against src family kinases and Bcr-Abl at IC50s of 100 and 90 nM, respectively. The bcr-abl fusion gene product, a consecutively activated tyrosine kinase, which is crucial for the development of chronic myeloid leukaemia (CML), is highly sensitive to bosutinib. Interestingly, distinctly lower concentrations of the dual src/abl inhibitor are required to ablate Bcr-Abl phosphorylation when compared to first-generation tyrosine kinase inhibitor imatinib (IM). Bosutinib is a potent inhibitor of CML cell proliferation in vitro and in vivo experiments and has demonstrated promising harbouring results in CML patients resistance or intolerance to IM in ongoing phase I/II clinical trials. Remarkably, bosutinib has been found to be capable of overcoming the majority of IM-resistant bcr-abl mutations. A randomised open label phase III clinical study to compare the efficacy of bosutinib and IM in first-line therapy of Ph+ chronic phase (CP) CML has recently been initiated. In a phase I/II clinical study with subjects suffering from advanced stages of solid tumours, long-term responses have also been reported. In conclusion, Bosutinib is a promising novel small molecule inhibitor for targeted therapy of CML and solid tumours.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Boschelli DH, Ye F et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44(23):3965–3977
Bruemmendorf TH, Cervantes F, et al (2008) Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 26(Suppl):abstr. 7001
Chung SW, Daniel R et al (1996) The ABL genes in normal and abnormal cell development. Crit Rev Oncog 7(1–2):33–48
Coluccia AM, Benati D et al (2006) SKI-606 decreases growth and motility of colorectal Âcancer cells by preventing pp 60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66(4): 2279–2286
Donato NJ, Wu JY et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690–698
Gambacorti-Passerini C, Kantarjian HM, et al (2008) Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. J Clin Oncol 26 May 20 (Suppl):abstr. 7049
Golas JM, Arndt K et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63(2):375–381
Golas JM, Lucas J et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65(12):5358–5364
Hu Y, Swerdlow S et al (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 103(45):16870–16875
Jallal H, Valentino ML et al (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67(4):1580–1588
Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651–659
Laneuville P (1995) Abl tyrosine protein kinase. Semin Immunol 7(4):255–266
Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-Âpositive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1): 19–26
Lutz MP, Esser IB et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243(2):503–508
Mazurenko NN, Kogan EA et al (1992) Expression of pp 60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28(2–3): 372–377
Messersmith WA, Krishnamurthi S, Hewes BA, Zacharchuk CM, Abbas R, Martins P, Dowling E, Volkert A, Martin E, Daud AI (2007) Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J Clin Oncol 25:abstr. 3552
Ottenhoff-Kalff AE, Rijksen G et al (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52(17):4773–4778
Pendergast AM (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8(2): 174–181
Ptasznik A, Nakata Y et al (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10(11): 1187–1189
Puttini M, Coluccia AM et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl Âinhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66(23): 11314–11322
Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40(2 Suppl 2):4–10
Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337–358
Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609
Verbeek BS, Vroom TM et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4):383–388
Vultur A, Buettner R et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185–1194
Zhang J, Kalyankrishna S et al (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366–376
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Keller, G., Schafhausen, P., Brümmendorf, T.H. (2010). Bosutinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 184. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01222-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-01222-8_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01221-1
Online ISBN: 978-3-642-01222-8
eBook Packages: MedicineMedicine (R0)